191 related articles for article (PubMed ID: 38229444)
1. Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.
Samuels SL; Chajecki A; Hu P; Kayser M; Weyman K; Pan B; Brown EA; Van Name M; Wolf RM
Diabetes Obes Metab; 2024 Apr; 26(4):1305-1313. PubMed ID: 38229444
[TBL] [Abstract][Full Text] [Related]
2. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
[TBL] [Abstract][Full Text] [Related]
3. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.
Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
Diabetes Obes Metab; 2019 Nov; 21(11):2542-2552. PubMed ID: 31364233
[TBL] [Abstract][Full Text] [Related]
4. Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.
Davies M; Alibegovic AC; Anil G; Braae UC; Jensen AB; Nordsborg RB
Diabet Med; 2024 May; 41(5):e15267. PubMed ID: 38088483
[TBL] [Abstract][Full Text] [Related]
5. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Fadini GP; Sciannameo V; Franzetti I; Bottigliengo D; D'Angelo P; Vinci C; Berchialla P; Arena S; Buzzetti R; Avogaro A;
Diabetes Obes Metab; 2019 Aug; 21(8):1886-1894. PubMed ID: 30985052
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
[TBL] [Abstract][Full Text] [Related]
7. Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G).
Ohsugi M; Eguchi K; Thietje Mortensen J; Yamamoto Y; Ueki K
Diabetes Res Clin Pract; 2023 Sep; 203():110841. PubMed ID: 37481115
[TBL] [Abstract][Full Text] [Related]
8. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
9. Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.
Fadini GP; Frison V; Rigato M; Morieri ML; Simioni N; Tadiotto F; D'Ambrosio M; Paccagnella A; Lapolla A; Avogaro A
Acta Diabetol; 2020 Mar; 57(3):367-375. PubMed ID: 31673896
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.
Jiang Y; Bai HS; Liu GX; Wang SY; Yin L; Hou ZT; Zhao CY; Fan GJ
Front Endocrinol (Lausanne); 2024; 15():1347684. PubMed ID: 38524632
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.
Conget I; Mauricio D; Ortega R; Detournay B;
BMJ Open; 2016 Jul; 6(7):e010197. PubMed ID: 27466235
[TBL] [Abstract][Full Text] [Related]
14. Is insulin the preferred treatment for HbA1c >9%?
Bloomgarden Z
J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
[TBL] [Abstract][Full Text] [Related]
15. Long-acting glucagon-like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study.
Lisco G; Bartolomeo N; De Tullio A; De Pergola G; Guastamacchia E; Jirillo E; Piazzolla G; Triggiani V; Giagulli VA
Andrology; 2024 Mar; 12(3):633-642. PubMed ID: 37615353
[TBL] [Abstract][Full Text] [Related]
16. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area.
Mata-Cases M; Franch-Nadal J; Ortega E; Real J; Gratacòs M; Vlacho B; Mauricio D
Curr Med Res Opin; 2019 Oct; 35(10):1735-1744. PubMed ID: 31081693
[No Abstract] [Full Text] [Related]
18. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes.
Falcetta P; Nicolì F; Citro F; Ciccarone A; Garofolo M; Del Prato S; Bianchi C
Acta Diabetol; 2023 Jan; 60(1):53-60. PubMed ID: 36166172
[TBL] [Abstract][Full Text] [Related]
19. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
20. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
Terauchi Y; Usami M; Inoue T
Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
